Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Brain Research, Collaborative Innovation Center for Brain Science, Huazhong University of Science and Technology, Wuhan, China.
Department of Pathophysiology, Key Lab of Neurological Disorder of Education Ministry, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Brain Research, Collaborative Innovation Center for Brain Science, Huazhong University of Science and Technology, Wuhan, China.
Biol Psychiatry. 2019 May 1;85(9):769-781. doi: 10.1016/j.biopsych.2018.12.008. Epub 2018 Dec 19.
Death-associated protein kinase 1 (DAPK1) is a widely distributed serine/threonine kinase that is critical for cell death in multiple neurological disorders, including Alzheimer's disease and stroke. However, little is known about the role of DAPK1 in the pathogenesis of Parkinson's disease (PD), the second most common neurodegenerative disorder.
We used Western blot and immunohistochemistry to evaluate the alteration of DAPK1. Quantitative polymerase chain reaction and fluorescence in situ hybridization were used to analyze the expression of microRNAs in PD mice and patients with PD. Rotarod, open field, and pole tests were used to evaluate the locomotor ability. Immunofluorescence, Western blot, and filter traps were used to evaluate synucleinopathy in PD mice.
We found that DAPK1 is posttranscriptionally upregulated by a reduction in microRNA-26a (miR-26a) caused by a loss of the transcription factor CCAAT enhancer-binding protein alpha. The overexpression of DAPK1 in PD mice is positively correlated with neuronal synucleinopathy. Suppressing miR-26a or upregulating DAPK1 results in synucleinopathy, dopaminergic neuron cell death, and motor disabilities in wild-type mice. In contrast, genetic deletion of DAPK1 in dopaminergic neurons by crossing DAT-Cre mice with DAPK1 floxed mice effectively rescues the abnormalities in mice with chronic MPTP treatment. We further showed that DAPK1 overexpression promotes PD-like phenotypes by direct phosphorylation of α-synuclein at the serine 129 site. Correspondingly, a cell-permeable competing peptide that blocks the phosphorylation of α-synuclein prevents motor disorders, synucleinopathy, and dopaminergic neuron loss in the MPTP mice.
miR-26a/DAPK1 signaling cascades are essential in the formation of the molecular and cellular pathologies in PD.
凋亡相关蛋白激酶 1(DAPK1)是一种广泛分布的丝氨酸/苏氨酸激酶,在包括阿尔茨海默病和中风在内的多种神经退行性疾病的细胞死亡中起着关键作用。然而,对于 DAPK1 在帕金森病(PD)发病机制中的作用知之甚少,PD 是第二常见的神经退行性疾病。
我们使用 Western blot 和免疫组织化学来评估 DAPK1 的变化。使用定量聚合酶链反应和荧光原位杂交来分析 PD 小鼠和 PD 患者中的 microRNAs 表达。旋转棒、旷场和棒测试用于评估运动能力。免疫荧光、Western blot 和滤膜陷阱用于评估 PD 小鼠中的突触核蛋白病。
我们发现,转录因子 CCAAT 增强子结合蛋白α缺失导致 microRNA-26a(miR-26a)减少,从而导致 DAPK1 在后转录水平上调。PD 小鼠中 DAPK1 的过表达与神经元突触核蛋白病呈正相关。在野生型小鼠中,抑制 miR-26a 或上调 DAPK1 会导致突触核蛋白病、多巴胺能神经元细胞死亡和运动障碍。相反,通过将 DAT-Cre 小鼠与 DAPK1 基因敲除小鼠杂交,在多巴胺能神经元中遗传删除 DAPK1 可有效挽救慢性 MPTP 处理小鼠的异常。我们进一步表明,DAPK1 过表达通过直接在丝氨酸 129 位点磷酸化α-突触核蛋白来促进 PD 样表型。相应地,一种可渗透细胞的竞争肽可阻止α-突触核蛋白的磷酸化,从而防止 MPTP 小鼠的运动障碍、突触核蛋白病和多巴胺能神经元丢失。
miR-26a/DAPK1 信号级联在 PD 的分子和细胞病理学形成中是必不可少的。